Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?

Balancing the therapeutic advantages of a medicine with its possible risks and side effects is an important part of medical practice and drug regulation. When a drug is designed to treat a particular disease or medical condition ends up causing additional risks or side effects that lead to the development of other serious health problems, it can have detrimental consequences for patients. This article explores the correlation between persistent proton pump inhibitor (PPI) use and hypertension, a common cardiovascular ailment. While PPIs are beneficial in treating various gastrointestinal problems, their availability without a prescription has resulted in self-medication and long-term use without medical monitoring. Recent findings have revealed a link between long-term PPI usage and increased cardiovascular risks, particularly hypertension. This study investigates the intricate mechanisms underlying PPI’s effects, focusing on potential pathways contributing to hypertension, such as endothelial dysfunction, disruption of nitric oxide bioavailability, vitamin B deficiency, hypocalcemia, and hypomagnesemia. The discussion explains how long-term PPI use can disrupt normal endothelial function, vascular control, and mineral balance, eventually leading to hypertension. The article emphasizes the significance of using PPIs with caution and ongoing research to better understand the implications of these medications on cardiovascular health.

[1]  Shenglin Jiang,et al.  The Efficacy and Safety of Proton Pump Inhibitors Combining Dual Antiplatelet Therapy in Patients with Coronary Intervention: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials , 2023, Reviews in Cardiovascular Medicine.

[2]  A. Eid,et al.  Inflammation and hypertension: Underlying mechanisms and emerging understandings , 2023, Journal of cellular physiology.

[3]  M. Kusumoto,et al.  Monitoring of serum magnesium levels during long-term use of proton pump inhibitors in elderly japanese patients: is it really necessary or not? , 2022, Journal of pharmaceutical health care and sciences.

[4]  C. Tack,et al.  Hypomagnesemia and Cardiovascular Risk in Type 2 Diabetes , 2022, Endocrine reviews.

[5]  Safeera Khan,et al.  The Effects of Proton Pump Inhibitors in Acid Hypersecretion-Induced Vitamin B12 Deficiency: A Systematic Review (2022) , 2022, Cureus.

[6]  K. Red-Horse,et al.  Vascular endothelial cell development and diversity , 2022, Nature Reviews Cardiology.

[7]  J. de Batlle,et al.  Evolution of the consumption trend of proton pump inhibitors in the Lleida Health Region between 2002 and 2015 , 2022, BMC Public Health.

[8]  Jin-fang Xu,et al.  Updated Insights on Cardiac and Vascular Risks of Proton Pump Inhibitors: A Real-World Pharmacovigilance Study , 2022, Frontiers in Cardiovascular Medicine.

[9]  M. Volpe,et al.  Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications , 2022, Frontiers in Medicine.

[10]  Changhao Sun,et al.  Association of dietary calcium, magnesium, sodium, and potassium intake and hypertension: a study on an 8-year dietary intake data from the National Health and Nutrition Examination Survey , 2021, Nutrition research and practice.

[11]  Robert E. Cohen,et al.  Association between proton pump inhibitors and periodontal disease severity , 2021, Clinical and experimental dental research.

[12]  R. Memon,et al.  Effects of Proton Pump Inhibitors on Serum Calcium Level: A Study on Rabbit Model , 2021, Journal of Pharmaceutical Research International.

[13]  H. McNulty,et al.  Associations of atrophic gastritis and proton-pump inhibitor drug use with vitamin B-12 status, and the impact of fortified foods, in older adults , 2021, The American journal of clinical nutrition.

[14]  S. Bhatia,et al.  Unravelling the involvement of gut microbiota in type 2 diabetes mellitus. , 2021, Life sciences.

[15]  J. Linseisen,et al.  Association of proton pump inhibitor use with endothelial function and metabolites of the nitric oxide pathway: A cross‐sectional study , 2021, Pharmacotherapy.

[16]  O. Senn,et al.  Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis , 2021, Therapeutic advances in gastroenterology.

[17]  R. Valera,et al.  Adverse Effects Associated with Proton Pump Inhibitor Use , 2021, Cureus.

[18]  M. Barbagallo,et al.  Magnesium and Hypertension in Old Age , 2020, Nutrients.

[19]  A. Anjankar,et al.  Vitamin B12 - Do You Know Everything? , 2020, Journal of Evolution of Medical and Dental Sciences.

[20]  Rajwinder Kaur,et al.  Pleotropic Effects of Polyphenols in Cardiovascular System. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  Ayaz Ahmad,et al.  A retrospective study on prescribing pattern and cost analysis of proton‐pump inhibitors used among adults of Saudi Arabia , 2020 .

[22]  J. Tanus-Santos,et al.  Consistent gastric pH-dependent effects of suppressors of gastric acid secretion on the antihypertensive responses to oral nitrite. , 2020, Biochemical pharmacology.

[23]  C. Sperati,et al.  Drug-Induced Hypertension. , 2019, Endocrinology and metabolism clinics of North America.

[24]  S. Ima-Nirwana,et al.  Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved , 2019, International journal of environmental research and public health.

[25]  J. Belizán,et al.  Mechanisms Involved in the Relationship between Low Calcium Intake and High Blood Pressure , 2019, Nutrients.

[26]  J. Tanus-Santos,et al.  Nitrite-stimulated Gastric Formation of S-nitrosothiols As An Antihypertensive Therapeutic Strategy. , 2019, Current drug targets.

[27]  A. Pottegård,et al.  Use of proton pump inhibitors among Danish children: A 16‐year register‐based nationwide study , 2019, Basic & clinical pharmacology & toxicology.

[28]  Avinash B. Kumar,et al.  The risks of long-term use of proton pump inhibitors: a critical review , 2018, Therapeutic advances in drug safety.

[29]  M. Iancu,et al.  Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review , 2018, Acta cardiologica.

[30]  G. Corrao,et al.  Use of proton pump inhibitors and risk of ischemic events in the general population. , 2018, Atherosclerosis.

[31]  Xian Wang,et al.  Homocysteine causes vascular endothelial dysfunction by disrupting endoplasmic reticulum redox homeostasis , 2018, Redox biology.

[32]  Qingze Fan,et al.  Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital , 2018, BMC Health Services Research.

[33]  Joshua W. Miller Proton Pump Inhibitors, H2-Receptor Antagonists, Metformin, and Vitamin B-12 Deficiency: Clinical Implications. , 2018, Advances in nutrition.

[34]  N. Ishimura,et al.  Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use , 2018, Journal of neurogastroenterology and motility.

[35]  M. Hlatky,et al.  Long‐term use of proton pump inhibitors, dose–response relationship and associated risk of ischemic stroke and myocardial infarction , 2018, Journal of internal medicine.

[36]  P. Bytzer,et al.  Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication , 2017, World journal of gastroenterology.

[37]  A. Mangoni,et al.  Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance , 2017, Scientific Reports.

[38]  Yong-Qing Wang,et al.  A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors , 2017, Advances in Therapy.

[39]  G. Cheng,et al.  Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro‐esophageal reflux disease: a meta‐analysis , 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[40]  D. Peura,et al.  25 Years of Proton Pump Inhibitors: A Comprehensive Review , 2016, Gut and liver.

[41]  A. Zullo,et al.  Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression , 2016, BMC Medicine.

[42]  T. Card,et al.  Proton pump inhibitor prescribing patterns in the UK: a primary care database study , 2016, Pharmacoepidemiology and drug safety.

[43]  M. Bolanowski,et al.  Effects of long-term administration of pantoprazole on bone mineral density in young male rats , 2016, Pharmacological reports : PR.

[44]  E. Savarino,et al.  Are proton pump inhibitors really so dangerous? , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[45]  J. Cooke,et al.  Proton Pump Inhibitors Accelerate Endothelial Senescence. , 2016, Circulation research.

[46]  J. Hallas,et al.  Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study , 2016, Therapeutic advances in gastroenterology.

[47]  J. Cooke,et al.  How May Proton Pump Inhibitors Impair Cardiovascular Health? , 2016, American Journal of Cardiovascular Drugs.

[48]  J. Tanus-Santos,et al.  Gastric S-nitrosothiol formation drives the antihypertensive effects of oral sodium nitrite and nitrate in a rat model of renovascular hypertension. , 2015, Free radical biology & medicine.

[49]  F. Messerli,et al.  Drug induced hypertension--An unappreciated cause of secondary hypertension. , 2015, European journal of pharmacology.

[50]  M. Rodríguez-Moran,et al.  Prevalence of Prehypertension in Mexico and Its Association With Hypomagnesemia. , 2015, American journal of hypertension.

[51]  Y. Bae,et al.  Association of Magnesium Intake with High Blood Pressure in Korean Adults: Korea National Health and Nutrition Examination Survey 2007–2009 , 2015, PloS one.

[52]  P. Ganguly,et al.  Role of homocysteine in the development of cardiovascular disease , 2015, Nutrition Journal.

[53]  J. Toh,et al.  Hypomagnesaemia associated with long-term use of proton pump inhibitors , 2014, Gastroenterology report.

[54]  G. Panagopoulos,et al.  Potential Costs of Inappropriate Use of Proton Pump Inhibitors , 2014, The American journal of the medical sciences.

[55]  J. Pines,et al.  Rising rates of proton pump inhibitor prescribing in US emergency departments. , 2014, The American journal of emergency medicine.

[56]  Z. Kopczyński,et al.  [Endothelial dysfunction in patients with primary hypertension and hyperhomocysteinemia]. , 2014, Postepy higieny i medycyny doswiadczalnej.

[57]  D. Corley,et al.  Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. , 2013, JAMA.

[58]  J. Tanus-Santos,et al.  TEMPOL enhances the antihypertensive effects of sodium nitrite by mechanisms facilitating nitrite-derived gastric nitric oxide formation. , 2013, Free radical biology & medicine.

[59]  N. Shah,et al.  Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine , 2013, Circulation.

[60]  J. Heidelbaugh Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications , 2013, Therapeutic advances in drug safety.

[61]  S. Bu,et al.  Daily calcium intake and its relation to blood pressure, blood lipids, and oxidative stress biomarkers in hypertensive and normotensive subjects , 2012, Nutrition research and practice.

[62]  J. Tanus-Santos,et al.  Increase in gastric pH reduces hypotensive effect of oral sodium nitrite in rats. , 2012, Free radical biology & medicine.

[63]  J. Chenot,et al.  Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care , 2012, International journal of clinical practice.

[64]  D. Metz,et al.  Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? , 2012, International journal of clinical practice.

[65]  U. Förstermann,et al.  Nitric oxide synthases: regulation and function. , 2012, European heart journal.

[66]  M. Neves,et al.  Magnesium and Vascular Changes in Hypertension , 2012, International journal of hypertension.

[67]  J. Cooke,et al.  DDAH says NO to ADMA. , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[68]  T. Cundy,et al.  Proton pump inhibitors and severe hypomagnesaemia , 2011, Current opinion in gastroenterology.

[69]  R. Jensen,et al.  Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium , 2010, Current gastroenterology reports.

[70]  J. Mackay,et al.  Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. , 2010, QJM : monthly journal of the Association of Physicians.

[71]  P. Sipponen,et al.  Hypochlorhydric stomach: a risk condition for calcium malabsorption and osteoporosis? , 2010, Scandinavian journal of gastroenterology.

[72]  P. Stover,et al.  Vitamin B12 and older adults , 2010, Current opinion in clinical nutrition and metabolic care.

[73]  V. Rodriguez,et al.  Molecular mechanisms triggered by low-calcium diets , 2009, Nutrition Research Reviews.

[74]  K. Insogna,et al.  The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism , 2009, The American Journal of Gastroenterology.

[75]  T. Cundy,et al.  Severe hypomagnesaemia in long‐term users of proton‐pump inhibitors , 2008, Clinical endocrinology.

[76]  Aleksander S Popel,et al.  Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. , 2008, Antioxidants & redox signaling.

[77]  Mark T. Gladwin,et al.  The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics , 2008, Nature Reviews Drug Discovery.

[78]  James Spalding,et al.  Proton Pump Inhibitor Utilization Patterns in Infants , 2007, Journal of pediatric gastroenterology and nutrition.

[79]  P. Patel,et al.  Role of Proton Pump Inhibitors in Calcium Absorption, Bone Resorption, and Risk of Hip Fracture , 2007 .

[80]  T. Lüscher,et al.  Nitric Oxide in Hypertension , 2006, Journal of clinical hypertension.

[81]  C. O'Morain,et al.  Review article: the long‐term use of proton‐pump inhibitors , 2005, Alimentary pharmacology & therapeutics.

[82]  A. Murray,et al.  Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. , 2005, The American journal of medicine.

[83]  N. Weiss Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function. , 2005, Current drug metabolism.

[84]  G. Werstuck,et al.  Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease , 2004, Cell Death and Differentiation.

[85]  P. Tsao,et al.  Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence , 2003, Circulation.

[86]  M. Orellana,et al.  Homocysteine and Essential Hypertension , 2003, Journal of clinical pharmacology.

[87]  S. Lentz,et al.  Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. , 2003, Atherosclerosis. Supplements.

[88]  J. Loscalzo,et al.  Influence of Hyperhomocysteinemia on the Cellular Redox State – Impact on Homocysteine-Induced Endothelial Dysfunction , 2003, Clinical chemistry and laboratory medicine.

[89]  R. Böger The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. , 2003, Cardiovascular research.

[90]  S. Gallus,et al.  Hospital use of acid‐suppressive medications and its fall‐out on prescribing in general practice: a 1‐month survey , 2003, Alimentary pharmacology & therapeutics.

[91]  R. Böger Association of Asymmetric Dimethylarginine and Endothelial Dysfunction , 2003, Clinical chemistry and laboratory medicine.

[92]  K. Bønaa,et al.  Relation between low calcium intake, parathyroid hormone, and blood pressure. , 2000, Hypertension.

[93]  O. Chonan,et al.  Effect of L-lactic acid on calcium absorption in rats fed omeprazole. , 1998, Journal of nutritional science and vitaminology.

[94]  P. Whelton,et al.  Hypertension , 1942, Nature Reviews Disease Primers.

[95]  N. Shah,et al.  Essential hypertension , 1942, Medical times.

[96]  E. Savarino,et al.  The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. , 2017, European journal of internal medicine.

[97]  C. Stefanadis,et al.  The role of nitric oxide on endothelial function. , 2012, Current vascular pharmacology.

[98]  C. Ponticelli,et al.  Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.